Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women

References

• Pecker LH, Lanzkron S. Sickle cell disease. Ann Intern Med. 2021;174(1):ITC1–ITC16. doi: 10.7326/aitc202101190
   PubMed Web of Science ®Google Scholar
• Nickel RS, Maher JY, Hsieh MH, Davis MF, Hsieh MM, Pecker LH. Fertility after curative therapy for sickle cell disease: a comprehensive review to guide care. J Clin Med. 2022;11(9):2318. doi: 10.3390/jcm11092318
   PubMed Web of Science ®Google Scholar
• Kroner BL, Hankins JS, Pugh N, et al. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol. 2022;97(5):603–612. doi: 10.1002/ajh.26495
   PubMed Web of Science ®Google Scholar
• Chandra A, Copen C, Stephen E. Infertility and impaired fecundity in the United States, 1982-2010: data from the national survey of family growth [Internet]. 2013. Available from: https://www.cdc.gov/nchs/data/nhsr/nhsr067.pdf
   Google Scholar
• Kesse-Adu R, Cartwright R, Thomas N, et al. Feritility and attitudes to fertility in a cohort of women with sickle cell disease in South East London. Blood. 2013;122(21):4686–4686. doi: 10.1182/blood.v122.21.4686.4686
   Web of Science ®Google Scholar
• Pecker LH, Hussain S, Mahesh J, et al. Diminished ovarian reserve in young women with sickle cell anemia. Blood. 2022;139(7):1111–1115. doi: 10.1182/blood.2021012756
   PubMed Web of Science ®Google Scholar
• Quinn CT, Ware RE. Reproductive equity: preserve the reserve. Blood. 2022;139(7):963–965. doi: 10.1182/blood.2021015021
   PubMed Web of Science ®Google Scholar
• Pecker LH, Oteng-Ntim E, Nero A, et al. Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care. Lancet Haematol. 2022;10(3):e225–e234. doi: 10.1016/s2352-3026(22)00353-2
   Web of Science ®Google Scholar
• Pecker LH, Sharma D, Nero A, et al. Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. Brit J Haematol. 2021;194(6):970–979. doi: 10.1111/bjh.17658
   PubMed Web of Science ®Google Scholar
• Meacham LR, Pecker LH, Gee B, et al. Incorporating gonadal health counseling into pediatric care of sickle cell patients. Hematology. 2022;2022(1):442–449. doi: 10.1182/hematology.2022000382
   PubMedGoogle Scholar
• Pecker LH, Kuo KHM. Go the distance reproductive health care for people with sickle cell disease. Hematol Oncol Clin N Am. 2022;36(6):1255–1270. doi: 10.1016/j.hoc.2022.07.010
   PubMed Web of Science ®Google Scholar
• Nahata L, Quinn GP, Strouse JJ, et al. Addressing fertility in adolescent boys with sickle cell disease: emerging clinical and ethical dilemmas. Blood Adv. 2023;7(18):5351–5353. doi: 10.1182/bloodadvances.2023010292
   PubMed Web of Science ®Google Scholar
• Pecker LH, Nero A, Christianson M. No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease. Hematology. 2022;2022(1):459–466. doi: 10.1182/hematology.2022000381
   PubMedGoogle Scholar
• Meier ER, Rampersad A. Pediatric sickle cell disease - past successes and future challenges. Pediatr Res. Published online October 5, 2016;81(1–2):1–37. doi: 10.1038/pr.2016.204
   Web of Science ®Google Scholar
• Sharma D, Day ME, Stimpson SJ, et al. Acute vaso-occlusive pain is temporally associated with the onset of menstruation in women with sickle cell disease. J Women Health. 2019;28(2):162–169. doi: 10.1089/jwh.2018.7147
   Web of Science ®Google Scholar
• Segbefia C, Campbell J, Tartaglione I, et al. Pain frequency and health care utilization patterns in women with sickle cell disease experiencing menstruation-associated pain crises. J Women’s Heal. 2023;32(12):1284–1291. doi: 10.1089/jwh.2023.0023
   PubMed Web of Science ®Google Scholar
• Roe AH, Lang B, McAllister A, et al. Contraceptive use and preferences among females with sickle cell disease. Contraception. Published online 2021. 2022;105:42–45. doi: 10.1016/j.contraception.2021.08.009
   PubMed Web of Science ®Google Scholar
• Pecker LH, Hussain S, Lanzkron S, et al. Women with sickle cell disease report low knowledge and use of long acting reversible contraception. J Natl Med Assoc. 2021;113(5):552–559. doi: 10.1016/j.jnma.2021.05.005
   PubMed Web of Science ®Google Scholar
• Pecker LH, Burke A, Streiff MB, et al. Progestin-only contraception is first line for sickle cell disease: a comment on “Hormonal therapies in females with blood disorders: thrombophilia, thrombosis, hemoglobinopathies, and anemias. Res Pr Thromb Haemost. 2023;7(6):102183. doi: 10.1016/j.rpth.2023.102183
   PubMed Web of Science ®Google Scholar
• Chavis WM, Norman GS. Sexuality and sickle cell disease. J Natl Med Assoc. 1993;85(2):113–116.
   PubMed Web of Science ®Google Scholar
• Adesoye OB, Akhigbe RE. Predictors of sex-induced crisis, sexual function and marital satisfaction in women with sickle cell disease. J Sex Med. 2022;19(11):1625–1633. doi: 10.1016/j.jsxm.2022.07.013
   PubMed Web of Science ®Google Scholar
• Stevenson E, Tanabe P, Knisely M, et al. Infertility and treatment‐seeking practices among females and males with sickle cell disease in the sickle cell disease implementation consortium registry. Pediatr Blood Cancer. 2023;70(7):e30356. doi: 10.1002/pbc.30356
   PubMed Web of Science ®Google Scholar
• Garba SR, Makwe CC, Osunkalu VO, et al. Ovarian reserve in Nigerian women with sickle cell anaemia: a cross- sectional study. J Ovarian Res. 2021;14(1):174. doi: 10.1186/s13048-021-00927-5
   PubMed Web of Science ®Google Scholar
• Early ML, Eke AC, Gemmill A, et al. Severe maternal morbidity and mortality in sickle cell disease in the national inpatient sample, 2012-2018. JAMA Netw Open. 2023;6(2):e2254552. doi: 10.1001/jamanetworkopen.2022.54552
   PubMed Web of Science ®Google Scholar
• Early ML, Malinowski AK, Solow M, et al. Trajectory of blood pressure in pregnant people with sickle cell disease: a multinational study. Blood. 2022;140(Supplement 1):8305–8307. doi: 10.1182/blood-2022-162334
   Google Scholar
• Queiroz AM, Lobo CDC, Ballas SK. Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy. Hematol Transfus Cell Ther. Published online 2020;43(3):386–388. doi: 10.1016/j.htct.2020.06.009
   PubMedGoogle Scholar
• Sukhera J. Narrative reviews: flexible, rigorous, and practical. J Grad Méd Educ. 2022;14(4):414–417. doi: 10.4300/jgme-d-22-00480.1
   PubMedGoogle Scholar
• Pecker LH, Maher JY, Law JY, et al. Risks associated with fertility preservation for women with sickle cell anemia. Fertil Steril. 2018;110(4):720–731. doi: 10.1016/j.fertnstert.2018.05.016
   PubMed Web of Science ®Google Scholar
• Missontsa MM, Bernaudin F, Fortin A, et al. Ovarian tissue cryopreservation for fertility preservation before hematopoietic stem cell transplantation in patients with sickle cell disease: safety, ovarian function follow-up, and results of ovarian tissue transplantation. J Assist Reprod Genet. Published online 2023:1–8. doi: 10.1007/s10815-024-03054-4
   Google Scholar
• Uchida N, Stasula U, Demirci S, et al. Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model. Nat Commun. 2023;14(1):6291. doi: 10.1038/s41467-023-41153-5
   PubMed Web of Science ®Google Scholar
• Creary MS. Bounded justice and the limits of health equity. J Law Med Ethics. 2021;49(2):241–256. doi: 10.1017/jme.2021.34
   PubMed Web of Science ®Google Scholar
• Mishkin AD, Mapara MY, Barhaghi M, et al. Fertility concerns and access to care for stem cell transplantation candidates with sickle cell disease. Biol Blood Marrow Transplant. 2020;26(8):e192–e197. doi: 10.1016/j.bbmt.2020.03.025
   PubMed Web of Science ®Google Scholar
• Kanter J, Smith WR, Desai PC, et al. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020;4(16):3804–3813. doi: 10.1182/bloodadvances.2020001743
   PubMed Web of Science ®Google Scholar
• Nabhan AF, Mburu G, Elshafeey F, et al. Women’s reproductive span: a systematic scoping review. Hum Reprod Open. 2022;2022(2):hoac005. doi: 10.1093/hropen/hoac005
   PubMedGoogle Scholar
• Faddy MJ, Gosden RG, Gougeon A, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod (Oxf, Engl). 1992;7(10):1342–1346. doi: 10.1093/oxfordjournals.humrep.a137570
   PubMed Web of Science ®Google Scholar
• Marca AL, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Updat. 2014;20(1):124–140. doi: 10.1093/humupd/dmt037
   PubMed Web of Science ®Google Scholar
• Penzias A, Azziz R, Bendikson K, et al. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Sterility. 2020 Dec;114(6):1151–1157. doi: 10.1016/j.fertnstert.2020.09.134
   PubMed Web of Science ®Google Scholar
• Pecker LH, Hussain S, Christianson MS, et al. Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the multicenter study of hydroxycarbamide. Brit J Haematol. 2020;191(5):880–887. doi: 10.1111/bjh.16976
   PubMed Web of Science ®Google Scholar
• Kopeika J, Oyewo A, Punnialingam S, et al. Ovarian reserve in women with sickle cell disease. Asnani MR, ed. PLoS One. 2019;14(2):e0213024. doi: 10.1371/journal.pone.0213024
   PubMed Web of Science ®Google Scholar
• Joseph L, Manceau S, Borderie D, et al. Detrimental effects of sickle cell disease and hydroxycarbamide on ovarian reserve but uncertain impact on fertility. Blood Adv. 2023;7(17):4794–4798. doi: 10.1182/bloodadvances.2022008859
   PubMed Web of Science ®Google Scholar
• Elchuri SV, Williamson RS, Brown RC, et al. The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia. Blood Cells Mol Dis. 2015;55(1):56–61. doi: 10.1016/j.bcmd.2015.03.012
   PubMed Web of Science ®Google Scholar
• Quinn GP, Stearsman DK, Campo-Engelstein L, et al. Preserving the right to future children: an ethical case analysis. Am J Bioeth. 2012;12(6):38–43. doi: 10.1080/15265161.2012.673688
   PubMed Web of Science ®Google Scholar
• Carrithers BK, Mathias J, Montana MP, et al. Knowledge of fertility and perception of fertility treatment among adults with sickle cell disease (KNOW FERTILITY). Blood. 2021;138(Supplement 1):3101–3101. doi: 10.1182/blood-2021-154040
   Google Scholar
• Day M, Bonnet K, Schlundt DG, et al. Vaso-occlusive pain and menstruation in sickle cell disease: a focus group analysis. Women’s Heal Reports. 2020;1(1):36–46. doi: 10.1089/whr.2019.0008
   Google Scholar
• Karafin MS, Singh M, Ceesay M, et al. Dyspareunia is associated with chronic pain in premenopausal women with sickle cell disease. Hematology. 2018;23(8):531–536. doi: 10.1080/10245332.2018.1430521
   PubMed Web of Science ®Google Scholar
• Pecker LH, Sharma D. Menstruation and sickle cell disease: ease her pain. J Women’s Heal. 2023;32(12):1265–1267. doi: 10.1089/jwh.2023.0581
   PubMed Web of Science ®Google Scholar
• Ogunsile FJ, Naik R, Lanzkron S. Overcoming challenges of venous thromboembolism in sickle cell disease treatment. Expert Rev Hematol. 2019;12(3):173–182. doi: 10.1080/17474086.2019.1583554
   PubMed Web of Science ®Google Scholar
• Naik RP, Streiff MB, Nelson JA, et al. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443–449. doi: 10.1016/j.amjmed.2012.12.016
   PubMed Web of Science ®Google Scholar
• Cockrum RH, Soo J, Ham SA, et al. Association of progestogens and venous thromboembolism among women of reproductive age. Obstet Gynecol. 2022;140(3):477–487. doi: 10.1097/aog.0000000000004896
   PubMed Web of Science ®Google Scholar
• Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018;3(1):9. doi: 10.1186/s40834-018-0064-y
   PubMedGoogle Scholar
• Watson A, Yarger J, Sedlander E, et al. Concern that contraception affects future fertility: how common is this concern among young people and does it stop them from using contraception? Contracept: X. 2023;5:100103. doi: 10.1016/j.conx.2023.100103
   PubMedGoogle Scholar
• Adesina OO, Brunson A, Fisch SC, et al. Pregnancy outcomes in women with sickle cell disease in California. Am J Hematol. 2023;98(3):440–448. doi: 10.1002/ajh.26818
   PubMed Web of Science ®Google Scholar
• McCaw-Binns A, Campbell L, Harris A, et al. Maternal mortality among women with sickle cell disease in Jamaica over two decades (1998–2017). EClinicalMedicine. 2022;43:101238. doi: 10.1016/j.eclinm.2021.101238
   PubMedGoogle Scholar
• Boghossian NS, Greenberg LT, Saade GR, et al. Association of sickle cell disease with racial disparities and severe maternal morbidities in black individuals. JAMA Pediatr. 2023;177(8):808. doi: 10.1001/jamapediatrics.2023.1580
   PubMed Web of Science ®Google Scholar
• Pecker LH, Boghossian NS, Saade G. US trends in maternal mortality by racial and ethnic group. JAMA. 2023;330(18):1799–1799. doi: 10.1001/jama.2023.17544
   PubMedGoogle Scholar
• Swarray-Deen A, Asare EV, Brew RA, et al. Sustainability of low maternal mortality in pregnant women with SCD in a low-resource setting. Blood Adv. 2022;6(7):1977–1980. doi: 10.1182/bloodadvances.2021005942
   PubMed Web of Science ®Google Scholar
• Brucato M, Lance E, Lanzkron S, et al. Developmental disorders in children born to women with sickle cell disease: a report from the Boston Birth Cohort. EJHaem. 2022;3(3):894–898. doi: 10.1002/jha2.478
   PubMedGoogle Scholar
• Sharma D, Kozanoğlu I, Ataga KI, et al. Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel. Blood Adv. 2024;8(4):1018–1029. doi: 10.1182/bloodadvances.2023011301
   PubMed Web of Science ®Google Scholar
• Creary S, Pecker LH, Quinn GP, et al. Comment on: infertility and treatment‐seeking practices among females and males with sickle cell disease in the sickle cell disease implementation consortium registry. Pediatr Blood Cancer. 2023;70(9):e30487. doi: 10.1002/pbc.30487
   Web of Science ®Google Scholar
• Andemariam B, Nielsen PH, Zillmer R, et al. ASCENT1: a phase 2 trial to evaluate the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease. Blood. 2022;140(Supplement 1):5420–5421. doi: 10.1182/blood-2022-169283
   Google Scholar
• Meacham LR, George S, Veludhandi A, et al. Female reproductive health outcomes after hematopoietic cell transplantation for sickle cell disease: is reduced intensity better than myeloablative conditioning? Transpl Cell Ther. 2023;29(8):.e531.1–.e531.4. doi: 10.1016/j.jtct.2023.05.004
   Google Scholar
• Early ML, Strodel RJ, Lake IV, et al. Acceptable, hopeful, and useful: development and mixed-method evaluation of an educational tool about reproductive options for people with sickle cell disease or trait. J Assist Reprod Genet. 2022;39(1):183–193. doi: 10.1007/s10815-021-02358-z
   PubMed Web of Science ®Google Scholar
• Vali S, Mukhtar S, Nandi A, et al. Cumulative outcome of pre-implantation genetic diagnosis for sickle cell disease: a 5-year review. Br J Haematol. 2020;52(5):875–879. doi: 10.1111/bjh.16930
   Google Scholar
• Oversight of Assisted Reproductive Technology [Internet]. Available from: https://www.asrm.org/advocacy-and-policy/media-and-public-affairs/oversite-of-art/
   Google Scholar
• Mamsen LS, Kristensen SG, Pors SE, et al. Consequences of β-thalassemia or sickle cell disease for ovarian follicle number and morphology in girls who had ovarian tissue cryopreserved. Front Endocrinol. 2021;11:593718. doi: 10.3389/fendo.2020.593718
   PubMed Web of Science ®Google Scholar
• Medicine PC of the AS for R. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–1033. doi: 10.1016/j.fertnstert.2019.09.013
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Pecker L. Pain without gain: steroids and sickle crisis. Blood. 2022;139(26):3678–3679. doi: 10.1182/blood.2022016070
   PubMed Web of Science ®Google Scholar
• Damlaj M, Alahmari B, Alaskar A, et al. Favorable outcome of non‐myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: A single center experience of 200 patients. Am J Hematol. Published online 2024. 2024;99(6):1023–1030. doi: 10.1002/ajh.27295
   PubMed Web of Science ®Google Scholar
• Han PKJ, Klein WMP, Arora NK. Varieties of uncertainty in health care: a conceptual taxonomy. Méd Decis Mak. 2011;31(6):828–838. doi: 10.1177/0272989x10393976
   PubMed Web of Science ®Google Scholar
• Quinn GP, Vadaparampil ST, Lee JH, et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol. 2009;27(35):5952–5957. doi: 10.1200/jco.2009.23.0250
   PubMed Web of Science ®Google Scholar
• Letourneau JM, Ebbel EE, Katz PP, et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer. 2012;118(6):1710–1717. doi: 10.1002/cncr.26459
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408. doi: 10.1002/ajh.21699
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672. doi: 10.1016/s0140-6736(11)60355-3
   PubMed Web of Science ®Google Scholar
• Dexter D, McGann PT. Hydroxyurea for children with sickle cell disease in sub‐Saharan Africa: a summary of the evidence, opportunities, and challenges. Pharmacother J Hum Pharmacol Drug Ther. 2023;43(5):430–441. doi: 10.1002/phar.2792
   Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi: 10.1056/nejm199505183322001
   PubMed Web of Science ®Google Scholar
• Liebelt EL, Balk SJ, Faber W, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea. Birth Defects Res Part B. 2007;80(4):259–366. doi: 10.1002/bdrb.20123
   PubMedGoogle Scholar
• Linton EA, Williams EC, Early ML, et al. Family planning needs of young adults with sickle cell disease. eJHaem. Published online 2023. 2023;4(3):587–594. doi: 10.1002/jha2.711
   PubMedGoogle Scholar
• Campen J, Silcock L, Yau S, et al. A novel non‐invasive prenatal sickle cell disease test for all at‐risk pregnancies. Brit J Haematol. 2020;190(1):119–124. doi: 10.1111/bjh.16529
   PubMed Web of Science ®Google Scholar
• Westin ER, Tsao DS, Atay O, et al. Validation of single‐gene noninvasive prenatal testing for sickle cell disease. Am J Hematol. 2022;97(7):E270–E273. doi: 10.1002/ajh.26570
   PubMed Web of Science ®Google Scholar
• Attia M, Kripalani S, Darbari I, et al. Parents of children with sickle cell disease are interested in preimplantation genetic testing. J Pediatrics. 2020;223:178–182.e2. doi: 10.1016/j.jpeds.2020.04.027
   PubMed Web of Science ®Google Scholar
• Pecker LH, Kappa S, Greenfest A, et al. Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle cell anemia. J Paediatr. 2018;201:221–228.e16. doi: 10.1016/j.jpeds.2018.05.019
   PubMed Web of Science ®Google Scholar
• Montalembert M, Voskaridou E, Oevermann L, et al. Real‐Life experience with hydroxyurea in patients with sickle cell disease: results from the prospective ESCORT‐HU cohort study. Am J Hematol. 2021;96(10):1223–1231. doi: 10.1002/ajh.26286
   PubMed Web of Science ®Google Scholar
• Pecker LH, Darbari DS. Psychosocial and affective comorbidities in sickle cell disease. Neurosci Lett. 2019;705:1–6. doi: 10.1016/j.neulet.2019.04.011
   PubMed Web of Science ®Google Scholar
• Essien EA, Winter-Eteng BF, Onukogu CU, et al. Psychosocial challenges of persons with sickle cell anemia: a narrative review. Medicine. 2023;102(47):e36147. doi: 10.1097/md.0000000000036147
   PubMed Web of Science ®Google Scholar
• Crosby LE, Walton A, Shook LM, et al. Development of a hydroxyurea decision aid for parents of children with sickle cell anemia. J Pediatr Hematol Oncol. 2018;41(1):56–63. doi: 10.1097/mph.0000000000001257
   Web of Science ®Google Scholar
• Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010;85(8):611–613. doi: 10.1002/ajh.21749
   PubMed Web of Science ®Google Scholar
• Carrithers B, Raja M, Gemmill A, et al. Knowledge of fertility and perception of fertility treatment among adults with sickle cell disease (KNOW FERTILITY). Front Glob Women’s Heal. 2023;4:1191064. doi: 10.3389/fgwh.2023.1191064
   PubMedGoogle Scholar
• Brawley OW, Cornelius LJ, Edwards LR, et al. National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease. Annals of internal medicine. 2008;148(12):932–938. doi: 10.7326/0003-4819-148-12-200806170-00220
   PubMed Web of Science ®Google Scholar
• de MM, Roberts I. Sickle cell disease: primum non nocere (first do no harm). Haematologica. 2010;95(1):4–5. doi: 10.3324/haematol.2009.020172
   PubMed Web of Science ®Google Scholar
• Jimenez CT, Scott RB, Henry WL, et al. Studies in sickle cell anemia: xxvi. the effects of homozygous sickle cell disease on the onset of menarche, pregnancy, fertility, pubescent changes, and body growth in negro subjects. Am J Dis Child. 1966;111(5):497–504. doi: 10.1001/archpedi.1966.02090080075005
   Google Scholar
• Desai P, Little J, Kanter J, et al. Kneeling was the first step for sickle cell disease. Ann Intern Med. 2021;174(7):1004–1005. doi: 10.7326/m20-7418
   PubMed Web of Science ®Google Scholar
• Ozuah PO. Gene therapy for sickle cell disease-a debt to be paid. JAMA Pediatr. 2021;175(6):565–566. doi: 10.1001/jamapediatrics.2020.7147
   PubMed Web of Science ®Google Scholar
• Farooq F, Mogayzel PJ, Lanzkron S, et al. Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. JAMA Netw Open. 2020;3(3):e201737. doi: 10.1001/jamanetworkopen.2020.1737
   PubMed Web of Science ®Google Scholar
• Collaborators G SCDThomson AM, McHugh TA, et al. Global burden of sickle cell disease in 2021 - authors’ reply. Lancet Haematol. Published online 2023. 2023;10(10):e792–e793. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00118-7/fulltext
   PubMed Web of Science ®Google Scholar
• Pecker LH, Schaefer BA, Luchtman-Jones L. Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol. [cited 2016 Dec 16];176(4):515–526. doi: 10.1111/bjh.14444
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012;120(22):4304–10–quiz 4448. doi: 10.1182/blood-2012-03-419879
   PubMed Web of Science ®Google Scholar
• Karkoska K, Todd K, Niss O, et al. Implementation of near‐universal hydroxyurea uptake among children with sickle cell anemia: a single‐center experience. Pediatr Blood Cancer. 2021;68(6):e29008. doi: 10.1002/pbc.29008
   PubMed Web of Science ®Google Scholar
• Khargekar N, Banerjee A, Athalye S, et al. Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis. Syst Rev. 2024;13(1):60. doi: 10.1186/s13643-024-02461-z
   PubMedGoogle Scholar
• Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203–205. doi: 10.1002/ajh.21905
   PubMed Web of Science ®Google Scholar
• Harris KM, Preiss L, Varughese T, et al. Examining mental health, education, employment, and pain in sickle cell disease. JAMA Netw Open. 2023;6(5):e2314070. doi: 10.1001/jamanetworkopen.2023.14070
   PubMed Web of Science ®Google Scholar
• Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94. doi: 10.7326/0003-4819-148-2-200801150-00004
   PubMed Web of Science ®Google Scholar
• Kanter J, Meier ER, Hankins JS, et al. Improving outcomes for patients with sickle cell disease in the United States. JAMA Heal Forum. 2021;2(10):e213467. doi: 10.1001/jamahealthforum.2021.3467
   PubMedGoogle Scholar
• Pecker LH, Hussain S, Mahesh J, et al. Hydroxyurea is a potential risk factor for diminished ovarian reserve in young adults with sickle cell anemia. Blood. 2020;136(Supplement 1):6–7. doi: 10.1182/blood-2020-136011
   PubMedGoogle Scholar
• Aharoni T, Amit-Danhi E, Overbeck M, et al. “You’d be right to indulge some skepticism”: trust-building strategies in future-oriented news discourse. J Stud. 2023;24(13):1651–1671. doi: 10.1080/1461670x.2023.2241086
   PubMed Web of Science ®Google Scholar
• Cell and gene therapy (CGT) access model | CMS [Internet]. Available from: https://www.cms.gov/priorities/innovation/innovation-models/cgt
   Google Scholar